Our pipelines cover over 11 CAR-T candidates including targeting GPC3, CD19, BCMA, Claudin18.2, EGFR/EGFRvIII, etc., five of which are at the stage of clinical trials.
  • Exploratory
    Clinical Studies
  • IND
  • Registered Clinical Trials
  • NDA
*GPC3 CAR-T (Glypican-3)

IND Approved

Hepatocellular Carcinoma / NSCLC

CAR-GPC3 T cell: the second generation of CAR-T with a humanized scFv targeting GPC3 for treatment of hepatocellular carcinoma and lung squamous carcinoma.

BCMA CAR-T
(B-Cell Maturation Antigen)

IND Approved

Multiple Myeloma

CAR-BCMA T cell: the second generation of CAR-T with a fully human scFv targeting BCMA for treatment of multiple myeloma.

CD19 CAR-T

IND Submitted

B Cell Leukemia / Lymphoma

CAR-CD19 T cell : the second generation of CAR-T with a humanized scFv targeting CD19 for treatment of lymphoma.

*CLDN 18.2 CAR-T(Claudin 18.2)

IND In Preparation

Gastric / Pancreatic / Esophageal Cancer

CAR-CLDN18.2 T cell : the second generation of CAR-T with a humanized scFv targeting claudin18.2 for treatment of gastric and pancreatic cancer.

*EGFR/EGFRvIII CAR-T
(Epidermal Growth Factor Receptor/variant3)

GBM / Other Solid Tumor

CAR-EGFR/EGFRvIII T cell :the second generation of CAR-T product with a humanized scFv targeting over-expressed EGFR as well as EGFRvIII for treatment of GBM (Glioblastoma Multiforme).

*: First-In-Human (means the first clinical trial for the CAR-T cells directed to the said target)